Cancer metastasis is the result of several independent processes, such as detachment of cancer cells from the primary tumor, cancer cell migration and invasion into the surrounding tissue, access to blood and lymphatic vessels, and colonization at the new location. All of these events require a breakdown of the extracellular matrix. This breakdown is mediated by several extracellular proteases. The plasminogen activation system is active in a number of nonpathologic tissueremodeling processes, including wound healing (1 ) and postlactation mammary gland involution (2 ) , whereas uncontrolled activity of the plasminogen activation system has been observed during pathologic conditions, including cancer invasion and metastasis (3 ) . The urokinase plasminogen activator receptor (uPAR), 3 which consists of 3 domains (domains I, II, and III), is an extracellular protein anchored to the plasma membrane via a glycosylphosphatidylinositol moiety located on domain III (4 ) . uPAR, which plays a central role in the plasminogen activation system, is present in high concentrations at the invasive front of human cancers, where proteolytic capacity is needed. Immunohistochemical studies of breast cancer, prostate cancer, and colorectal cancer (CRC) have shown that uPAR is present in macrophages and neutrophils at the invasive front (5-7 ). In colon cancer, uPAR is also localized to budding cancer cells (7 ) . uPAR can be shed from the cell surface as soluble uPAR (suPAR). Increased uPAR concentrations occur in tumor tissue and in the blood of cancer patients. In both tumor tissue and blood, high uPAR concentrations have been shown to correlate with a poor prognosis in several types of cancer (8 ) . The use of immunoassays that measure a combination of different uPAR forms has demonstrated that uPAR concentrations in extracts of tumor tissue samples from CRC patients are an independent prognostic factor for 5-year overall survival (9 ) , and there are indications that uPAR concentrations correlate with liver metastasis (10 ) . The plasma suPAR concentration has also been correlated with survival in CRC patients (11 ) . uPAR can be cleaved in the linker region between domains I and II by its ligand, urokinase plasminogen (13 ) . Thus, the concentrations of the individual cleaved uPAR forms could be indicators of the activity of the plasminogen activation system, and the cleavage products may be stronger prognostic markers than the total amount of the uPAR forms. To test this hypothesis, we designed specific immunoassays to measure the individual uPAR forms (14 ) . These assays demonstrated that the uPAR(I) concentration is a stronger prognostic factor than the total concentration of the uPAR forms (15 ) . In blood, the concentration of the different uPAR forms is lower than in tumor extracts. The majority of blood samples have a uPAR(I) concentration below the limit of quantification (LOQ) when it is measured with time-resolved fluorescence immunoassay 3 (TR-FIA 3) (16, 17 ) . Therefore, an improved assay with a lower LOQ is needed to measure the uPAR(I) concentration in all blood samples. Our aim in the present study was to identify monoclonal antibodies (mAbs) with increased affinities for uPAR(I) to enable the design of a TR-FIA with an improved functional sensitivity. The uPAR mAb R3 has previously been characterized (8, 14 ) . mAb R20 is derived from a fusion between myeloma cells and spleen cells from female NIHS mice deficient in uPAR and immunized with human recombinant soluble uPAR from transfected Chinese hamster ovary cells. A comparison of the reactivities of R3 and R20 against uPAR(I) and intact suPAR [suPAR(I-III)] by western blotting showed that R20 had a stronger reactivity toward liberated uPAR(I) (see Fig. 1A in the Data Supplement that accompanies the online version of this Brief Communication at http://www.clinchem.org/content/ vol56/issue10). Surface plasmon resonance analysis showed that the 2 mAbs have similar affinities for uPAR(I) and suPAR(I-III) (see Table 1 in the online Data Supplement). Simultaneous binding of R3 and R20 was possible only to the liberated uPAR(I) fragment and not to suPAR(I-III) (see Fig. 1B in the online Data Supplement). These mAbs were used for designing the assay, which was optimized with respect to the recovery of uPAR(I) in citrated plasma. The design of the final assay (TR-FIA 4) used R3 as the capture mAb at a concentration of 3.33 pmol/well and Eu-labeled R20 as the detecting mAb (see Fig. 2A in the online Data Supplement).
We demonstrated the reproducibility of the calibration curves by calculating the CVs for the calibration curves of 10 different plates. TR-FIA 4 successfully measured the uPAR(I) concentration over the entire concentration range tested (1.3-962 pmol/L); the CVs were Ͻ8% for all calibrators (see Fig. 2B in the online Data Supplement). We analyzed a 5-fold dilution series of purified recombinant uPAR(I) (0.062-962 pmol/L) in assay buffer or uPAR-depleted citrated plasma to evaluate the limit of detection and the LOQ. The limit of detection of TR-FIA 4 was 0.45 pmol/L uPAR(I), and the LOQ was 0.65 pmol/L (see the protocol in Supplemental File 1 of the online Data Supplement). The corresponding values for TR-FIA 3 are 1.9 pmol/L and 2.9 pmol/L, respectively (14 ) . Loss of linearity was observed at a concentration of 0.63 pmol/L uPAR(I), i.e., at virtually the same concentration as the LOQ.
uPAR depletion of citrated plasma produced a 96% decrease in signal. To determine the degree of crossreactivity of TR-FIA 4 with the different uPAR forms and to compare the result with that of TR-FIA 3, we added equimolar amounts of suPAR(I-III), suPAR(II-III), and uPAR(I) to assay buffer and measured the concentrations with the 2 assays. With the addition of the peptide uPAR antagonist AE120, TR-FIA 3 showed 5% cross-reactivity with suPAR(I-III) (14 ) , and TR-FIA 4 showed 11% cross-reactivity with suPAR(I-III). In samples with 34 and 240 pmol/L of added uPAR(I) calibrator, TR-FIA 4 showed intraassay CVs of 11% and 5%, respectively, and interassay CVs of 14% and 6%. The recovery of uPAR(I) added to citrated plasma diluted 1:5 in assay buffer (200 mL/L citrated plasma) was 103% as assessed with TR-FIA 4 (see Supplemental File 1 in the online Data Supplement). From the validation assessment we conclude that TR-FIA 4 can be used to measure uPAR(I) in citrated plasma. We then proceeded to investigate whether the uPAR(I) concentration measured with TR-FIA 4 had an improved prognostic performance for CRC compared with the uPAR(I) concentration measured with TR-FIA 3.
The clinical study cohort included 298 patients with primary CRC (patient characteristics are summarized in Table 2 Table 1 . The uPAR forms were all significantly associated with survival, with high concentrations predicting short overall survival. The hazard ratios were all Ͼ2 for a 2-fold difference in the concentrations of the different uPAR forms (Table 1) Several studies have demonstrated the prognostic strength of uPAR(I), even though many patient samples had nonmeasurable uPAR(I) concentrations because of the high LOQ of the earlier TR-FIA 3 assay (16 -18 ) . TR-FIA 4 relies only on the 2 mAbs R3 and R20. Given the improved functional sensitivity and the independence of the peptide antagonist AE120, we conclude that TR-FIA 4 is superior to TR-FIA 3 for measuring uPAR(I) in citrated plasma.
A previous study of preoperative plasma samples from a different CRC patient cohort showed that the concentration of the combined uPAR forms independently predicted survival (P Ͻ 0.0001 in a multivariate Cox analysis) (11 ) . The immunoassay used in that study uses the same capture mAb as TR-FIA 2 but a polyclonal anti-suPAR antibody as the detecting antibody (11 ) and measures intact uPAR (free and uPA-bound) and uPAR(II-III), but not uPAR(I). TR-FIA 2 measures free intact uPAR and uPAR(II-III), and the suPAR concentrations in donor citrated plasma obtained with these 2 assays are similar (8 ) . Given that the uPAR forms measured with TR-FIA 2 are significant prognostic markers (Table 1) , our study validates the results of this previous study. In the present study, uPAR(I) measured with TR-FIA 4, but not with TR-FIA 3, retained prognostic significance in the multivariate model (Table 1) . This finding supports the hypothesis that lowering the functional sensitivity of the uPAR(I) assay would improve the prognostic value of uPAR(I) measured in blood samples from CRC patients. Given that uPAR(I) has been shown to be a strong prognostic marker for other cancers (15, 16, 18 ) and a potential diagnostic marker (19 ) , it would be useful to measure the different uPAR forms in blood from healthy individuals adjusted for age and sex, to estimate a reference interval, and to test the utility of this new uPAR(I) assay in other cancer diseases. 
